검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cytokine-induced killer cells (Cytokine-induced killer cells) Allife Medical Science and Technol…·Cholangiocarcinoma 30% |
|---|---|
Overview Program | Cytokine-induced killer cells |
Overview Company | Allife Medical Science and Technology Co., Ltd. |
Overview Modality | CGT |
Overview Target | Cholangiocarcinoma |
Overview Indication | Cholangiocarcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target cancerous cells upon antigen |
MoA Biomarker | PD-1 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.. Patients with high-risk (HR) leukemia remain at substantial risk of early relapse, treatment-related toxicity, and poor survival, underscoring the need for effective relapse prevention therapies. To our knowledge, this firs… |
Clinical Primary efficacy | 30% |
Clinical OS | 16.67 |
Clinical Result source | ClinicalTrials.gov NCT02782546 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cytokine-induced killer cells (Cytokine-induced killer cells) Allife Medical Science and Technol…·Cholangiocarcinoma 30% |
|---|---|
Overview Program | Cytokine-induced killer cells |
Overview Company | Allife Medical Science and Technology Co., Ltd. |
Overview Modality | CGT |
Overview Target | Cholangiocarcinoma |
Overview Indication | Cholangiocarcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target cancerous cells upon antigen |
MoA Biomarker | PD-1 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.. Patients with high-risk (HR) leukemia remain at substantial risk of early relapse, treatment-related toxicity, and poor survival, underscoring the need for effective relapse prevention therapies. To our knowledge, this firs… |
Clinical Primary efficacy | 30% |
Clinical OS | 16.67 |
Clinical Result source | ClinicalTrials.gov NCT02782546 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교